Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
941-960 of 991 trials

Knee Surgery: Testing SRSD107 for Blood Clot Prevention

We are studying whether SRSD107 can effectively prevent blood clots in adults undergoing knee replacement surgery. We will also assess how safe it is compared to the standard treatment, enoxaparin.

Venous Thromboembolism6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyOrthopedics and Traumatology

GSK4418959 for Solid Tumors: A New Treatment Approach

We are investigating the safety and early effectiveness of the DNA-repair inhibitor GSK4418959 in adults with specific solid tumors. This study looks at the drug alone and with other cancer treatments to see how well it works.

Colorectal Cancer3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

High-Dose Influenza Vaccine for Adults 60 and Older

We are studying a new high-dose flu vaccine to see if it provides better immune protection than a standard vaccine for adults aged 60 and above. The trial will also assess the safety of this new vaccine.

Influenza Immunization1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Sickle Cell Disease: Tebapivat Study

We are investigating a new medication, tebapivat, to see if it helps improve anemia in people with sickle cell disease. The study will also look at its safety and effects on fatigue and pain.

Sickle Cell Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Gastric Cancer: Zolbetuximab with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for adults with advanced gastric cancer to see if it works better than standard therapies. This trial is for patients with specific tumor markers.

Gastric CancerMetastatic Gastric CancerGastroesophageal Junction AdenocarcinomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Myeloma: Comparing Treatment Approaches

We are studying two treatment plans for newly diagnosed multiple myeloma patients who cannot have a transplant. Our goal is to see which plan helps more patients reach a state of minimal disease.

Multiple MyelomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Cystic Fibrosis: Nebulized Bacteriophage Treatment

We are studying a new nebulized treatment for adults with cystic fibrosis and chronic Pseudomonas lung infection. The goal is to see if it helps reduce the infection and improve lung function and quality of life.

Cystic Fibrosis≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Non-Small Cell Lung Cancer: QL2107 vs. Keytruda®

We are comparing a new treatment, QL2107, to Keytruda® for patients with resected non-small cell lung cancer. The study aims to see if QL2107 works similarly in the body and to evaluate its safety and immune response.

Non-small Cell Lung Cancer1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Nucresiran for Transthyretin Amyloidosis with Cardiomyopathy

We are studying whether Nucresiran can help reduce serious heart-related events in patients with transthyretin amyloidosis. The trial compares its effects to a placebo to assess overall health improvements.

Transthyretin Amyloidosis with Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Rheumatoid Arthritis: Lower Dose of Rituximab Study

We are evaluating whether a 200 mg dose of Rituximab every six months is as effective as the standard 1 g dose for managing rheumatoid arthritis. This study will help us understand its impact on disease activity and overall patient well-being.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementRheumatology

Small-Cell Lung Cancer: Tarlatamab Combination Study

We are testing a new treatment combining tarlatamab with durvalumab, carboplatin, and etoposide for patients with untreated extensive stage small-cell lung cancer. The goal is to see if this combination helps improve survival compared to standard treatment.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Bisphosphonate Treatment for Primary Hyperparathyroidism

We are studying whether bisphosphonate treatment before parathyroid surgery can improve bone, kidney, and heart health one year after the procedure. This trial compares the treatment to a placebo to see if there are any benefits.

Primary Hyperparathyroidism1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

PMM2-CDG: GLM101 Treatment Study

We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.

Congenital Disorder of Glycosylation (CDG)6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHepatologyNeurology

Refractory Epilepsy: YCJ-01 Cannabis Extract

We are studying a cannabis extract to see if it can help reduce seizures in patients with difficult-to-control epilepsy due to Tuberous Sclerosis Complex. The trial will also assess the safety of this treatment.

Tuberous Sclerosis ComplexRefractory Epilepsy in Tuberous Sclerosis Complex6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Breast Cancer Treatment: Sac-TMT vs. Standard Chemotherapy

We are studying a new treatment for high-risk early-stage breast cancer to see if it works better than standard chemotherapy combined with pembrolizumab. This trial is for individuals with triple-negative or hormone receptor-low positive breast cancer.

Triple Negative Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Crohn’s Disease: Mirikizumab with Tirzepatide

We are studying whether a combination of mirikizumab and tirzepatide helps adults with moderately to severely active Crohn’s disease achieve better remission and weight loss than mirikizumab alone.

Crohn’s DiseaseObesity or Overweight1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Bipolar-I Disorder: Long-term Safety of KarXT

We are studying the long-term safety and tolerability of KarXT for people experiencing manic episodes in Bipolar-I Disorder. This trial aims to ensure that the treatment is safe for those affected.

Mania and Bipolar DisorderConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPsychiatry

Irritable Bowel Syndrome: Saccharomyces boulardii CNCM I-745

We are studying whether a probiotic can help adults with non-constipated IBS feel better and improve their quality of life compared to a placebo.

Non-constipated Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterology

Chronic Cluster Headache: Low-Dose LSD Study

We are investigating whether a low dose of LSD can help reduce the frequency and severity of chronic cluster headaches. This study will assess both its effectiveness and safety compared to a placebo.

Chronic Cluster Headache≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology